NASDAQ:VXRT

Vaxart Stock Predictions

Healthcare > Biotechnology

Buy VXRT

*Your capital is at risk

$0.600

-0.0049 (-0.81%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

VXRT Prediction Chart

VXRT Predictions History

Latest community submissions for VXRT.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
Michael Smith @MichaelSmith.138466	Mar 5, 2020	$2.55 +6.25%	$2.40	X	93.75%	1
JS Pro	Feb 28, 2020	$2.68 -6.62%	$2.85	X	94.04%	1
Samuel Sussman @SamuelSussman.142434	Feb 28, 2020	Bullish	$2.85	X	—	1
2poJeff Pro	Feb 28, 2020	$2.79 -2.79%	$2.85	X	97.89%	1
JS Pro	Feb 27, 2020	$1.75 -29.15%	$2.47	X	70.85%	1
RatFink	Feb 27, 2020	$2.70 +9.31%	$2.47	X	90.69%	1
JS Pro	Feb 24, 2020	$1.11 -13.28%	$1.28	X	86.72%	1
RatFink	Feb 24, 2020	$1.15 -10.16%	$1.28	X	89.84%	1
JS Pro	Feb 21, 2020	$1.15 +5.50%	$1.09	X	94.50%	0
JS Pro	Feb 20, 2020	$1.00 -8.26%	$1.09	X	91.74%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for VXRT with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT VAXART

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the t...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by